Vai al contenuto Vai al menu
Apri il menu Chiudi il menu

Pubblicazioni scientifiche

 

2023

  1. Bezzerri V, Gentili V, Api M, Finotti A, Papi C, Tamanini A, Boni C, Baldisseri E, Olioso D, Duca M, Tedesco E, Leo S, Borgatti M, Volpi S, Pinton P, Cabrini G, Gambari R, Blasi F, Lippi G, Rimessi A, Rizzo R, Cipolli M. SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation. Nat Commun. 2023 Jan 10;14(1):132.
  2. Conti J, Sorio C, Melotti P. Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis. Children 2023, 10, 4.
  3. Costa E, Girotti S, van den Ham HA, Cipolli M, van der Ent CK, Taylor-Cousar JL, Leufkens HGM. Traits, trends and hits of orphan drug designations in cystic fibrosis. J Cyst Fibros. 2023 Sep;22(5):949-957.
  4. Dajti E, Ravaioli F, Paiola G, Volpi S, Colecchia L, Ferrarese A, Alemanni LV, Cusumano C, Di Biase AR, Marasco G, Vestito A, Festi D, Rautou P, Cipolli M, Colecchia A. The non-invasive evaluation of liver involvement in patients with cystic fibrosis: A pro-spective study. Liver Int 2023 Nov; 43 (11): 2492-2502.
  5. Foroni S, Taha I, Bezzerri V, Pintani E, Cipolli M, Danesino C, Mazza T, Minelli A. The pathogenic variant c.258þ533_459þ403del in SBDS gene is the commonest rare variant in Italy and shows a founder effect. Gene Reports 31 (2023) 101775.
  6. Gramegna A, Aliberti S, Calderazzo MA, Casciaro R, Ceruti C, Cimino G, Fabrizzi B, Lucanto C, Messore B, Pisi G, Taccetti G, Tarsia P, Blasi F, Cipolli M. The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus. Respir Med. 2023 Dec;220:107455.
  7. Kawashima N, Bezzerri V, Corey SJ. The Molecular and Genetic Mechanisms of Inherited Bone Marrow Failure Syndromes: The Role of Inflammatory Cytokines in Their Pathogenesis. Biomolecules. 2023 Aug 16;13(8):1249.
  8. Kawashima N, Oyarbide U, Cipolli M, Bez-zerri V, Corey SJ. Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants. Haematologica. 2023 Oct 1;108(10):2594-2605.
  9. Kleinfelder K, Lotti V, Eramo A, Amato F, Lo Cicero S, Castelli G, Spadaro F, Farinazzo A, Dell’Orco D, Preato S, Conti J, Rodella L, Tomba F, Cerofolini A, Baldisseri E, Bertini M, Volpi S, Villella VR, Esposito S, Zollo I, Castaldo G, Laudanna C, Sorsher EJ, Hong J, Joshi D, Cutting G, Lucarelli M, Melotti P, Sorio C. In silico analysis and theratyping of an ultrarare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells. iScience 26, 108180, November 17, 2023.
  10. Kleinfelder K, Somenza E, Farinazzo A, Conti J, Lotti V, Latorre RV, Rodella L, Massella A, Tomba F, Bertini M, Sorio C, Melotti P. CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M; D1270N]/dele22_24. Int. J. Mol. Sci. 2023, 24, 5199.
  11. Kleinfelder K, Villella VR, Hristodor AM, Laudanna C, Castaldo G, Amato F, Melotti P, Sorio C. Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination. Int. J. Mol. Sci. 2023, 24, 10358.
  12. Landini N, Ciet P, Janssens HM, Bertolo S, Ros M, Mattone M, Catalano C, Majo F, Costa S, Gramegna A, Lucca F, Parisi GF, Saba L, Tiddens HAWM, Morana G. Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging. Front Pediatr. 2023 Feb 6; 10:1084313.
  13. Lucca F, Bezzerri V, Danese E, Olioso D, Pe-serico D, Boni C, Cucchetto G, Montagnana M, Tridello G, Meneghelli I, Ros M, Lippi G, Cipolli M. Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. Int J Mol Sci. 2023 Jan 4; 24(2):908.
  14. Peretto L, Tonetto E, Maestri I, Bezzerri V, Valli R, Cipolli M, Pinotti M, Balestra D. Counteracting the Common Shwachman-Diamond Syndrome-Causing SBDS c.258+2T>C Mutation by RNA Therapeutics and Base/Prime Editing. Int J Mol Sci. 2023 Feb 16;24(4):4024.
  15. Savi D, Lucca F, Tridello G, Meneghelli I, Comello I, Tomezzoli S, Signorini M, Proietti E, Cucchetto G, Volpi S, Cipolli M. Long-term clinical outcomes of elexa-caftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced-pulmonary disease. Respir Med. 2023 Nov-Dec; 219:107406.
  16. Sellers ZM, Assis DN, Paranjape SM, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan KS, Hunt WR, Leey J, Ling SC, Morelli G, Peckham D, Pettit RS, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead SE, Narkewicz MR. Cystic fibrosis screening, evaluation and management of hepatobiliary disease con-sensus recommendations. Hepatology. 2023 Oct 26. Epub ahead of print.
  17. Ullmann N, Santamaria F, Allegorico A, Fainardi V, Borrelli M, Ferraro VA, Proietti E, Parisi GF, Romagnoli V, Lucca F, Gallucci M, Mappa L, Lelli M, Amato D, Petrarca L, Ci-mino G, Sacco O, Calogero C, Patria MF, Acquafredda A, Ferlisi A, Maschio M, Kantar A, Cutrera R. Primary ciliary dyskinesia: A multicenter survey on clinical practice and patient management in Italy. Pediatr Pulmonol. 2023 Apr; 58(4):1127-1135.